CRISPR Therapeutics(CRSP) - 2023 Q4 - Annual Report

(Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37923 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation rece ...